[{"orgOrder":0,"company":"VantAI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VantAI \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"VantAI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VantAI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"VantAI","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":1.6699999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.6699999999999999,"dosageForm":"Undisclosed","sponsorNew":"VantAI \/ Blueprint Medicines","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ Blueprint Medicines"}]

Find Clinical Drug Pipeline Developments & Deals by VantAI

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          India Med Expo
                          Not Confirmed
                          India Med Expo
                          Not Confirmed

                          Details : The collaboration aims to pursue targets and mechanisms that have historically been considered undruggable or out of reach for traditional small-molecule or biologic therapeutics.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 20, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Blueprint Medicines

                          Deal Size : $1,670.0 million

                          Deal Type : Expanded Collaboration

                          blank

                          02

                          India Med Expo
                          Not Confirmed
                          India Med Expo
                          Not Confirmed

                          Details : The collaboration will focus on leveraging VantAI’s generative AI platform with BMS’s expertise in targeted protein degradation to discover and design molecular glues as small molecule therapeutics.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 13, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $674.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          India Med Expo
                          Not Confirmed
                          India Med Expo
                          Not Confirmed

                          Details : The organizations will leverage VantAI's geometric deep learning platform to computationally streamline the design of new molecules optimized for each E3 platform, leveraging unique target-E3 interface contacts to create innovative routes for important d...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 20, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank